Luna Genetics: Arthur Beaudet

In a filing with the US Securities and Exchange Comission, Exact Sciences said that board member Eli Casdin had submitted his resignation from the company's board of directors, effective Sept. 21. Casdin is the chief investment officer and founder of Casdin Capital, an investment firm focused on the life sciences and healthcare industry.

Quidel has appointed Robert Bujarski as chief operating officer effective Sept. 14. Bujarski had been Quidel's SVP of commercial operations in North America and general counsel since July 2019, SVP of business development from August 2009 through July 2019, and corporate secretary until February 2019.

Biofidelity has appointed Stephen Miller as chief commercial officer. Miller has held leadership positions at both public and private companies including Precipio, BG Medicine, Thermo Fisher Scientific, and Athena Diagnostics.

Fran Soistman has joined the scientific board of Alveo Technologies. He has more than 40 years of experience in the healthcare and managed care sector, including as executive vice president for Aetna. As a member of Alveo's scientific advisory board, Soistman will help guide the firm's efforts to implement its infectious disease testing technologies. Alameda, California-based Alveo is developing its be.well platform, a point-of-care, at-home diagnostic tool.

Veracyte has promoted Richard Kloos to executive medical director, overseeing the company's global medical affairs in all clinical areas addressed by its genomic tests. Kloos previously served as senior medical director of endocrinology at Veracyte, which he joined in 2012. He was previously a professor of endocrinology and metabolism, and nuclear medicine at Ohio State University, and was attending physician at the OSU Comprehensive Care Center. He was also codirector of the OSU Thyroid Cancer Unit and served a four-year term as secretary and chief operating officer for the American Thyroid Association.

Spatial gene expression analysis startup Vizgen has appointed Terry Lo as president and CEO, effective immediately. He has more than two decades of experience in developing commercialization strategies for life sciences companies, Vizgen said. Lo comes to Vizgen from Akoya Biosciences, where he was president. He has also held executive positions at PerkinElmer, Roche, Hologic, and Bristol-Myers Squibb. Lo has an MBA from the University of Chicago and a masters' degree in microbiology from Virginia Tech.

Interim CEO Peidong Wang will remain at Vizgen as VP of engineering.

GenMark Diagnostics said in a filing with the US Securities and Exchange Commission that Brian Mitchell, its senior vice president of operations, is no longer employed by the company.